Clolar and Tumour lysis syndrome - from FDA reports
Tumour lysis syndrome is found among people who take Clolar, especially for people who are female, 20-29 old , have been taking the drug for < 1 month, also take medication Cytarabine, and have Acute myeloid leukaemia. This review analyzes which people have Tumour lysis syndrome with Clolar. It is created by eHealthMe based on reports of 1,040 people who have side effects when taking Clolar from FDA , and is updated regularly.
What to expect?
You are not alone!
Personalized health information
On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>
On Nov, 14, 2017
1,040 people reported to have side effects when taking Clolar.
Among them, 34 people (3.27%) have Tumour lysis syndrome
Number of reports submitted per year:
Time on Clolar when people have Tumour lysis syndrome *:
- < 1 month: 100 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Tumour lysis syndrome when taking Clolar *:
- female: 51.52 %
- male: 48.48 %
Age of people who have Tumour lysis syndrome when taking Clolar *:
- 0-1: 0.0 %
- 2-9: 12.9 %
- 10-19: 22.58 %
- 20-29: 29.03 %
- 30-39: 12.9 %
- 40-49: 0.0 %
- 50-59: 3.23 %
- 60+: 19.35 %
Top conditions involved for these people *:
- Acute Myeloid Leukaemia (18 people, 52.94%)
- Preventive Health Care (9 people, 26.47%)
- Nausea (9 people, 26.47%)
- Acute Lymphocytic Leukemia (all) (9 people, 26.47%)
- Septic Shock (5 people, 14.71%)
Top co-used drugs for these people *:
- Cytarabine (17 people, 50.00%)
- Allopurinol (16 people, 47.06%)
- Acyclovir (10 people, 29.41%)
- Acetaminophen (8 people, 23.53%)
- Lasix (7 people, 20.59%)
Top other side effects for these people *:
- Hypotension (18 people, 52.94%)
- Multi-Organ Failure (12 people, 35.29%)
- Renal Failure Acute (10 people, 29.41%)
- Pain (7 people, 20.59%)
- Hypokalemia (7 people, 20.59%)
* Approximation only. Some reports may have incomplete information.
How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.
Subscribe to the study: get notified of updates to the study.
Want to find out more about the FDA reports used in the study? You can request them from FDA.
Do you have Tumour lysis syndrome when taking Clolar?
- Check symptoms - is tumour lysis syndrome caused by a drug or a condition?
- Get alerts to symptoms - forecast your symptoms and get alerts
- Join related support groups - you are not alone, join a support group on ehealth.me
- Report the side effect - help people in need and in real time
- Ask a question - ask a question related to the study
- write a review - share your experience related to the study
- More tools...
Expand the study to include all drugs with the same ingredientsTumour lysis syndrome and drugs with ingredients of clofarabine.
Expand the study to include reports from both FDA and eHealthMeTumour lysis syndrome and Clolar from FDA and eHealthMe reports
Clolar has active ingredients of clofarabine. (latest outcomes from Clolar 1,042 users)
Tumour lysis syndrome
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells) has been reported by people with multiple myeloma, chronic lymphocytic leukaemia, preventive health care, non-hodgkin's lymphoma, acute myeloid leukaemia (latest reports from 4,798 Tumour lysis syndrome patients).